Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      NOT_YET_RECRUITING
      A Phase 1/2 Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
      Description

      This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

      Conditions
      Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCDK Gene MutationCCND1 Gene AmplificationCDK4 Gene Amplification
      Talk to us
      COMPLETED
      A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
      Description

      This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of fisogatinib (formerly known as BLU- 554) administered orally in patients with FGF19 IHC+ hepatocellular carcinoma (HCC). The study consists of 3 parts, a dose-escalation part (Part 1), an expansion part (Part 2) exploring a once daily (qd) dosing schedule at the recommended Phase 2 dose (RP2D), and a Part 3 expansion of the qd dosing schedule at the RP2D in TKI naive patients.

      Conditions
      Hepatocellular Carcinoma (HCC)
      Talk to us